DUBLIN--(BUSINESS WIRE)--The "Immunoglobulin E (IgE) Allergy Blood Tests - Medical Devices Pipeline Assessment, 2019" report has been added to ResearchAndMarkets.com's offering.
This report provides an overview of Immunoglobulin E (IgE) Allergy Blood Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunoglobulin E (IgE) Allergy Blood Tests pipeline products.
Scope
- Extensive coverage of the Immunoglobulin E (IgE) Allergy Blood Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Immunoglobulin E (IgE) Allergy Blood Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Immunoglobulin E (IgE) Allergy Blood Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Key Topics Covered
1 Table of Contents
2 Introduction
2.1 Immunoglobulin E (IgE) Allergy Blood Tests Overview
3 Products under Development
3.1 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Stage of Development
3.2 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Segment
3.3 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Territory
3.4 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Regulatory Path
3.5 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Estimated Approval Date
4 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products under Development by Companies
4.1 Immunoglobulin E (IgE) Allergy Blood Tests Companies - Pipeline Products by Stage of Development
4.2 Immunoglobulin E (IgE) Allergy Blood Tests - Pipeline Products by Stage of Development
5 Immunoglobulin E (IgE) Allergy Blood Tests Companies and Product Overview
5.1 Abionic SA
5.2 Amerimmune LLC
5.3 AXO Science SAS
5.4 Biovator AB (Inactive)
5.5 Children's Hospital Boston
5.6 China Medical Technologies Inc (Inactive)
5.7 Cytognos, SL
5.8 EUROIMMUN US LLC
5.9 Ferrer inCode SL
5.10 HOB Biotech Group Suzhou Co Ltd
5.11 Hycor Biomedical Inc
5.12 Institut fur Produktqualitat GmbH
5.13 IRCCS San Raffaele Hospital
5.14 Medical Research Council
5.15 Stanford University
5.16 Thermo Fisher Scientific Inc
5.17 University of Connecticut Health Center
5.18 University of Nottingham
5.19 University of Queensland
5.20 VEGA Ltd
6 Immunoglobulin E (IgE) Allergy Blood Tests - Recent Developments
6.1 Sep 24, 2019: Theradiag announces improved results for H1 2019
6.2 Sep 05, 2019: Thermo Fisher Scientific elects New Director to Board
6.3 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership
6.4 Jul 29, 2019: Siemens Healthineers continues to drive growth forward
6.5 Jul 29, 2019: Changes in the Managing Board of Siemens Healthineers
6.6 Jul 29, 2019: OBN announce Thermo Fisher Scientific as a new Corporate Sponsor
6.7 Jul 24, 2019: Thermo Fisher Scientific reports second quarter 2019 results
6.8 Jul 18, 2019: Theradiag announces first-half revenue up 9%
6.9 Jul 01, 2019: Arrayit approved for Electronic Medicare Reimbursement from the Centers for Medicare and Medicaid Services
6.10 May 17, 2019: SenzaGen receives new order of SEK 0.5 m from a recurring customer
6.11 May 02, 2019: Siemens Healthineers posts strong revenue and profit growth in the second quarter
6.12 May 02, 2019: New method to analyze blood shows immune cell rare; likely not involved in food allergy
6.13 Apr 24, 2019: Thermo Fisher Scientific announces first quarter 2019 results
6.14 Apr 04, 2019: Theradiag and HOB Biotech settle their legal dispute
6.15 Mar 27, 2019: Theradiag reports its 2018 full-year results
6.16 Feb 25, 2019: Thermo Fisher Scientific launches new dosimetry monitoring service
6.17 Feb 20, 2019: Theradiag reports annual revenues for 2018 and its year-end cash position
6.18 Feb 11, 2019: Siemens Healthineers to invest EUR 350 million in new Campus Forchheim
6.19 Jan 30, 2019: Thermo Fisher Scientific reports fourth quarter and full year 2018 results
6.20 Jan 28, 2019: Arrayit allergy testing services endorsed by leading Pediatrics Medical Group
6.21 Dec 11, 2018: TheraDiag names Bertrand de Castelnau as Chief Executive Officer
6.22 Dec 04, 2018: 10 Billion Lab Tests and Growing: Siemens Healthineers Mass. Manufacturing Expansion Largely Completed
6.23 Dec 04, 2018: 10 billion lab tests and growing: Siemens Healthineers mass. manufacturing expansion largely completed
6.24 Nov 19, 2018: Arrayit announces allergy testing agreement with Sutter Health
6.25 Nov 07, 2018: Thermo Fisher Scientific names Jim Mullen to its board of directors
6.26 Nov 05, 2018: Siemens Healthineers with strong finish in fourth quarter, full year targets for fiscal 2018 achieved
6.27 Oct 31, 2018: Appointment of Pierre Morgon as chairman of the board of directors of Theradiag
For more information about this report visit https://www.researchandmarkets.com/r/o0wc75
